NEW YORK, July 30, 2018 /PRNewswire/ -- Phosphorus, a leader in diagnostic and bioinformatic solutions for clinical Next Generation Sequencing (NGS), announced today that Mark McDonough, most recently chief executive officer of CombiMatrix, has been named chief business officer.
"I'm very excited to be joining Phosphorus to help the company continue to grow and innovate in this rapidly-changing field of genomics," said Mark McDonough, chief business officer of Phosphorus. "As genomics continues to become a more ubiquitous part of our healthcare system, I'm excited to help position Phosphorus as a market leader and as an enabler of actionable insights."
Mr. McDonough has extensive experience building and leading commercial teams and businesses in life sciences, molecular diagnostics, and genomics. Prior to Phosphorus, Mr. McDonough led CombiMatrix as President and CEO for five years, culminating in the successful sale of the business to Invitae (NVTA). Before his time at CombiMatrix, Mr. McDonough held senior executive positions at Pathwork Dx and Labcorp. Also a former Naval officer, Mr. McDonough holds a B.S. in Finance from Miami University.
"The addition of a world class chief business officer to our team further strengthens our ability to build partnerships and reach more patients with potentially life-changing genetic information," said Alexander Bisignano, chief executive officer of Phosphorus. "With Mark's deep experience in the genomics world and proven track record of building winning teams and cultures, we are well positioned for the next phase of growth at Phosphorus."
About Phosphorus
Phosphorus's mission is to improve healthcare for everyone by better understanding and harnessing the power of the human genome. Having built the most comprehensive, high-quality, and cost-effective portfolio of genetic tests, Phosphorus is able to increase access and quality of care in the burgeoning field of genomics. Phosphorus currently provides panel-based, constitutional genetic testing in the specialty areas of Fertility, Cardiology, Lipidology, Oncology, Pharmacology, Ophthalmology, Neurology, and Pediatric/Metabolic disorders, while also offering the most advanced Whole Exome Sequencing test covering the most recent understanding of the human genome. Additionally, Phosphorus provides the Elements™ software platform to enable any laboratory to easily deploy any of the Phosphorus genetic tests on-premise as a local solution. For more information, please visit our website at phosphorus.com.
SOURCE Phosphorus
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article